Review of NICE Technology Appraisal Guidance No.192; Gefitinib for the first-line treatment of non-small cell lung cancer No.258; Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer and No.310; Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Proposal to move the existing guidance to the static list
TA192 and TA258 were added to the static list in December 2014. TA310 was due to be considered for review in April 2017.
NICE is currently updating the clinical guideline on the diagnosis and management of lung cancer.
No new evidence has been identified that is likely to lead to a change in the existing recommendations in TA192, TA258 and TA310.
Consequently TA192 and TA258 should remain on the static list, and TA310 should move to the static list. All three appraisals should also be incorporated into the forthcoming clinical guideline, which is due to be published in March 2019.
Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.
In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which will help us decide the best way to update this guidance.
Please see the stakeholder matrix for a full list of the organisations we have contacted.
This page was last updated: 14 February 2018